companies / splice-bio
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-04-29 json
| total_raised | 135,000,000135.0M | ○ |
|---|---|---|
| founded | null | |
| hq | Barcelona | |
| industry | unknown | |
| stage | series-b+ |
SpliceBio is a clinical-stage genetic medicines company using Protein Splicing to treat diseases caused by mutations in genes too large for a standard AAV vector. It develops therapies for inherited retinal and neurological disorders, led by SB-007 for Stargardt disease. Its platform splits and reassembles large proteins so AAV can deliver them.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-06-01 | series-b | 135,000,000135.0M | null | ○ |
Cloudflare, WordPress 7.0, MonsterInsights 10.1.3, Yoast SEO 27.6, Google Analytics, Google Tag Manager, jQuery Migrate 3.4.1, imagesLoaded 4.1.4, PHP, DoubleClick Floodlight, Contact Form 7 6.1.6, CookieYes
| fact | status | src |
|---|---|---|
| Series B, $135.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |